Literature DB >> 30745565

Precision dosing of warfarin: open questions and strategies.

Xi Li1,2, Dan Li1,2, Ji-Chu Wu3, Zhao-Qian Liu1,2, Hong-Hao Zhou1,2, Ji-Ye Yin4,5,6.   

Abstract

Warfarin has a very narrow therapeutic window and obvious interindividual variability in its effects, with many factors contributing to the body's response. Algorithms incorporating multiple genetic, environment and clinical factors have been established to select a precision dose for each patient. A number of randomized controlled trials (RCTs) were conducted to explore whether patients could benefit from these algorithms; however, the results were inconsistent. Some questions remain to be resolved. Recently, new genetic and non-genetic factors have been discovered to contribute to variability in optimal warfarin doses. The results of further RCTs have been unveiled, and guidelines for pharmacogenetically guided warfarin dosing have been updated. Based on these most recent advancements, we summarize some open questions in this field and try to propose possible strategies to resolve them.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30745565     DOI: 10.1038/s41397-019-0083-3

Source DB:  PubMed          Journal:  Pharmacogenomics J        ISSN: 1470-269X            Impact factor:   3.550


  83 in total

Review 1.  In vitro assessment of the allelic variants of cytochrome P450.

Authors:  Masahiro Hiratsuka
Journal:  Drug Metab Pharmacokinet       Date:  2011-11-01       Impact factor: 3.614

Review 2.  Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing.

Authors:  J A Johnson; L Gong; M Whirl-Carrillo; B F Gage; S A Scott; C M Stein; J L Anderson; S E Kimmel; M T M Lee; M Pirmohamed; M Wadelius; T E Klein; R B Altman
Journal:  Clin Pharmacol Ther       Date:  2011-09-07       Impact factor: 6.875

3.  CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant.

Authors:  Matthew G McDonald; Mark J Rieder; Mariko Nakano; Clara K Hsia; Allan E Rettie
Journal:  Mol Pharmacol       Date:  2009-03-18       Impact factor: 4.436

4.  A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose.

Authors:  Gregory M Cooper; Julie A Johnson; Taimour Y Langaee; Hua Feng; Ian B Stanaway; Ute I Schwarz; Marylyn D Ritchie; C Michael Stein; Dan M Roden; Joshua D Smith; David L Veenstra; Allan E Rettie; Mark J Rieder
Journal:  Blood       Date:  2008-06-05       Impact factor: 22.113

Review 5.  Warfarin pharmacogenetics: to genotype or not to genotype, that is the question.

Authors:  L H Cavallari; E A Nutescu
Journal:  Clin Pharmacol Ther       Date:  2014-07       Impact factor: 6.875

Review 6.  Warfarin pharmacogenetics.

Authors:  Julie A Johnson; Larisa H Cavallari
Journal:  Trends Cardiovasc Med       Date:  2014-09-06       Impact factor: 6.677

7.  CYP4F2 genetic variant alters required warfarin dose.

Authors:  Michael D Caldwell; Tarif Awad; Julie A Johnson; Brian F Gage; Mat Falkowski; Paul Gardina; Jason Hubbard; Yaron Turpaz; Taimour Y Langaee; Charles Eby; Cristi R King; Amy Brower; John R Schmelzer; Ingrid Glurich; Humberto J Vidaillet; Steven H Yale; Kai Qi Zhang; Richard L Berg; James K Burmester
Journal:  Blood       Date:  2008-02-04       Impact factor: 22.113

Review 8.  Oral anticoagulation: a critique of recent advances and controversies.

Authors:  Munir Pirmohamed; Farhad Kamali; Ann K Daly; Mia Wadelius
Journal:  Trends Pharmacol Sci       Date:  2015-02-17       Impact factor: 14.819

9.  A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose.

Authors:  Fumihiko Takeuchi; Ralph McGinnis; Stephane Bourgeois; Chris Barnes; Niclas Eriksson; Nicole Soranzo; Pamela Whittaker; Venkatesh Ranganath; Vasudev Kumanduri; William McLaren; Lennart Holm; Jonatan Lindh; Anders Rane; Mia Wadelius; Panos Deloukas
Journal:  PLoS Genet       Date:  2009-03-20       Impact factor: 5.917

10.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update.

Authors:  J A Johnson; K E Caudle; L Gong; M Whirl-Carrillo; C M Stein; S A Scott; M T Lee; B F Gage; S E Kimmel; M A Perera; J L Anderson; M Pirmohamed; T E Klein; N A Limdi; L H Cavallari; M Wadelius
Journal:  Clin Pharmacol Ther       Date:  2017-04-04       Impact factor: 6.875

View more
  5 in total

1.  CYP2C9 and VKORC1 genotyping for the quality of long-standing warfarin treatment in Russian patients.

Authors:  Elizaveta Panchenko; Ekaterina Kropacheva; Anatoly Dobrovolsky; Elena Titaeva; Oksana Zemlyanskaya; Dmitry Trofimov; Irina Galkina; Galina Lifshits; Natalya Vereina; Sergey Sinitsin; Nadezda Vorobyeva; Lyudmila Grehova; Dmitry Zateyshchikov; Irina Zotova; Tatyana Vavilova; Olga Sirotkina; Alevtina Grontkovskaya
Journal:  Pharmacogenomics J       Date:  2020-02-06       Impact factor: 3.550

Review 2.  Warfarin dosing strategies evolution and its progress in the era of precision medicine, a narrative review.

Authors:  Amr Mohamed Fahmi; Hazem Elewa; Islam El Jilany
Journal:  Int J Clin Pharm       Date:  2022-03-05

3.  Analytics of the clinical implementation of pharmacogenomics testing in 12 758 individuals.

Authors:  Yang Wang; Fan Xiao; Yan Chen; Le-Dong Xiao; Lei-Yun Wang; Yan Zhan; Xing-Liang Xiong; Gang Zhou; Rong Liu; Dong-Sheng Ouyang; Zhi Li; Howard L McLeod; Wei Zhang; Qing Li; Zhao-Qian Liu; Hong-Hao Zhou; Ji-Ye Yin
Journal:  Clin Transl Med       Date:  2021-11

Review 4.  The Relationship Among Intestinal Bacteria, Vitamin K and Response of Vitamin K Antagonist: A Review of Evidence and Potential Mechanism.

Authors:  Han Yan; Yi Chen; Hong Zhu; Wei-Hua Huang; Xin-He Cai; Dan Li; Ya-Juan Lv; Hong-Hao Zhou; Fan-Yan Luo; Wei Zhang; Xi Li
Journal:  Front Med (Lausanne)       Date:  2022-04-18

5.  Massively parallel characterization of CYP2C9 variant enzyme activity and abundance.

Authors:  Clara J Amorosi; Melissa A Chiasson; Matthew G McDonald; Lai Hong Wong; Katherine A Sitko; Gabriel Boyle; John P Kowalski; Allan E Rettie; Douglas M Fowler; Maitreya J Dunham
Journal:  Am J Hum Genet       Date:  2021-07-26       Impact factor: 11.025

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.